216 related articles for article (PubMed ID: 26385482)
21. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
22. RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network.
Geng L; Huntoon CJ; Karnitz LM
J Cell Biol; 2010 Oct; 191(2):249-57. PubMed ID: 20937699
[TBL] [Abstract][Full Text] [Related]
23. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
26. Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation.
Liu Q; Ghosh P; Magpayo N; Testa M; Tang S; Gheorghiu L; Biggs P; Paganetti H; Efstathiou JA; Lu HM; Held KD; Willers H
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1081-9. PubMed ID: 25832698
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
29. Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway.
Tang XL; Yan L; Zhu L; Jiao DM; Chen J; Chen QY
J Pharmacol Sci; 2017 Sep; 135(1):1-7. PubMed ID: 28939129
[TBL] [Abstract][Full Text] [Related]
30. Characterization of FANCL variants observed in patient cancer cells.
Frost MG; Mazloumi Aboukheili AM; Toth R; Walden H
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32420600
[TBL] [Abstract][Full Text] [Related]
31. The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP.
Li JJ; Ding Y; Li DD; Peng RQ; Feng GK; Zeng YX; Zhu XF; Zhang XS
Cancer Biol Ther; 2009 Oct; 8(20):1914-21. PubMed ID: 20009541
[TBL] [Abstract][Full Text] [Related]
32. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
Li W; Liu X; Zhang G; Zhang L
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
[TBL] [Abstract][Full Text] [Related]
33. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
Kachnic LA; Li L; Fournier L; Ferraiolo N; Dahm-Daphi J; Borgmann K; Willers H
Cancer Lett; 2011 Jun; 305(1):86-93. PubMed ID: 21414716
[TBL] [Abstract][Full Text] [Related]
34. The antitumor agent doxorubicin binds to Fanconi anemia group F protein.
Kusayanagi T; Tsukuda S; Shimura S; Manita D; Iwakiri K; Kamisuki S; Takakusagi Y; Takeuchi T; Kuramochi K; Nakazaki A; Sakaguchi K; Kobayashi S; Sugawara F
Bioorg Med Chem; 2012 Nov; 20(21):6248-55. PubMed ID: 23026082
[TBL] [Abstract][Full Text] [Related]
35. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
[TBL] [Abstract][Full Text] [Related]
37. Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways.
Su WP; Ho YC; Wu CK; Hsu SH; Shiu JL; Huang JC; Chang SB; Chiu WT; Hung JJ; Liu TL; Wu WS; Wu PY; Su WC; Chang JY; Liaw H
Sci Rep; 2017 Jun; 7(1):3879. PubMed ID: 28634400
[TBL] [Abstract][Full Text] [Related]
38. BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells.
Wang H; Bierie B; Li AG; Pathania S; Toomire K; Dimitrov SD; Liu B; Gelman R; Giobbie-Hurder A; Feunteun J; Polyak K; Livingston DM
Mol Cell; 2016 Jul; 63(2):277-292. PubMed ID: 27373334
[TBL] [Abstract][Full Text] [Related]
39. Silencing of fanconi anemia complementation group f exhibits potent chemosensitization of mitomycin C activity in breast cancer cells.
Yu J; Zhao L; Li Y; Li N; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
J Breast Cancer; 2013 Sep; 16(3):291-9. PubMed ID: 24155758
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E
Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
